Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia

Diego A. Pereira-Martins, Juan L. Coelho-Silva, Isabel Weinhauser, Pedro L. Franca-Neto, Douglas R. Silveira, Cesar Ortiz, Amanda Moreira-Aguiar, Marinus M. Lima, Luisa C. Koury, Raul A. de Melo, Ana B. Gloria, Evandro M. Fagundes, Bruno K. Lino, Katia Pagnano, Rosane Bittencourt, Elenaide Nunes, Fabiola Traina, Lorena Figueiredo-Pontes, Armand Keating, Martin S. TallmanRaul C. Ribeiro, Richard Dilon, Arnold Ganser, Miguel A. Sanz, Nancy Berliner, Peter Valk, Bob Lowenberg, Tiziana Ottone, Nelida Noguera, Maria T. Voso, Francesca Paoloni, Paola Fazi, Emanuele Ammatuna, Gerwin Huls, Jan Jacob Schuringa, Eduardo M. Rego, Antonio R. Lucena-Araujo*

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    3 Citations (Scopus)
    108 Downloads (Pure)

    Abstract

    Although a growing body of evidence demonstrates that altered mtDNA content (mtDNAc) has clinical implications in several types of solid tumours, its prognostic relevance in acute promyelocytic leukaemia (APL) patients remains largely unknown. Here, we show that patients with higher-than-normal mtDNAc had better outcomes regardless of tumour burden. These results were more evident in patients with low-risk of relapse. The multivariate Cox proportional hazard model demonstrated that high mtDNAc was independently associated with a decreased cumulative incidence of relapse. Altogether, our data highlights the possible role of mitochondrial metabolism in APL patients treated with ATRA.

    Original languageEnglish
    Pages (from-to)170-174
    Number of pages5
    JournalBritish Journal of Haematology
    Volume200
    Issue number2
    Early online date20-Oct-2022
    DOIs
    Publication statusPublished - Jan-2023

    Keywords

    • anthracycline-based chemotherapy
    • ATRA
    • mtDNA content
    • oxidative phosphorylation
    • RETINOIC ACID
    • ARSENIC TRIOXIDE
    • RAR-ALPHA
    • RISK

    Fingerprint

    Dive into the research topics of 'Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia'. Together they form a unique fingerprint.

    Cite this